Glucose Kabipac (Glucose Monohydrate)

Glucose Kabipac is indicated for several clinical situations where rapid carbohydrate supplementation or fluid replacement is required.

• Management of acute hypoglycemia in patients who cannot take oral glucose, providing a rapid rise in plasma glucose.
• Inclusion in total parenteral nutrition (TPN) solutions to supply carbohydrate calories for patients with non‑functional gastrointestinal tracts.
• Provision of isotonic fluid and electrolyte balance during surgery, trauma resuscitation, or severe dehydration.
• Maintenance of adequate blood glucose concentrations in critically ill or fasting individuals receiving intensive care.
• Use as a compatible diluent for intravenous medications that require a carbohydrate‑based carrier.

When administered intravenously, Glucose Kabipac may be associated with a range of adverse reactions, most of which are related to its osmotic and metabolic properties.

Common

• Transient hyperglycemia or elevated blood glucose levels.
• Local irritation or pain at the injection site.
• Mild electrolyte shifts, such as decreased serum potassium.
• Nausea or mild gastrointestinal discomfort.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Fluid overload or pulmonary edema in patients with compromised cardiac function.
• Hypersensitivity reactions, including rash, urticaria, or anaphylaxis.
• Metabolic acidosis in the setting of large-volume administration.

Clinicians should observe specific precautions when prescribing Glucose Kabipac to minimize risks and ensure safe use.

• Assess baseline blood glucose and adjust infusion rate in diabetic or hyperglycemic patients.
• Monitor fluid balance and cardiac status to avoid overload, especially in heart failure or renal impairment.
• Check serum electrolytes before and during therapy, correcting abnormalities as needed.
• Use aseptic technique and inspect the solution for particulate matter or discoloration before administration.
• Avoid rapid infusion rates that exceed recommended guidelines for osmolarity.
• Consider pregnancy and lactation status; limited data are available, so use only if clearly indicated.

Glucose Kabipac can interact with other medications or clinical conditions, influencing its safety or efficacy.

Avoid

• Co‑administration with insulin or other rapid‑acting glucose‑lowering agents without appropriate dose adjustments.
• Simultaneous infusion of high‑osmolarity solutions that may increase the risk of phlebitis.

Use with caution

• Concurrent use of diuretics that may exacerbate electrolyte disturbances.
• Administration alongside catecholamines or glucocorticoids, which can affect glucose metabolism.
• Patients receiving total parenteral nutrition containing other carbohydrate sources; monitor total caloric load.